News + Filings Holdings
All
13F
13D/G
Other
|
|
Velan Capital Investment Management LP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| Morgan Adam (10% Owner) has filed a Form 4 on ALIMERA SCIENCES INC|
Txns:
| Granted 50,000 options to buy
@ $2.99, valued at
$149.5k
|
|
| 08/17/2023 |
4
| Morgan Adam (10% Owner) has filed a Form 4 on ALIMERA SCIENCES INC|
Txns:
| Converted 4,845,392 shares
@ $1.7, valued at
$8.2M
Converted 2,924,762 shares
@ $2.1, valued at
$6.1M
Converted 4,178,725 shares
@ $1.7, valued at
$7.1M
Converted 8,117 options to buy
@ $0
Converted 7,000 options to buy
@ $0
Converted 6,000 options to buy
@ $0 |
|
| 08/16/2023 |
SC 13D/A
| Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc. |
| 08/11/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/03/2023 |
SC 13D/A
| Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc. |
| 06/28/2023 |
SC 13D/A
| Velan Capital Investment Management LP reports a 4% stake in Praxis Precision Medicines, Inc. |
| 05/19/2023 |
3
| Velan Capital Investment Management LP (10% Owner) has filed a Form 3 on ALIMERA SCIENCES INC |
| 05/19/2023 |
SC 13D/A
| Velan Capital Investment Management LP reports a 18.9% stake in Alimera Sciences, Inc. |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 03/31/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/20/2023 |
SC 13D
| Velan Capital Investment Management LP reports a 9.9% stake in Praxis Precision Medicines, Inc. |
| 02/27/2023 |
SC 13D
| Velan Capital Investment Management LP reports a 10.2% stake in Jasper Therapeutics, Inc. |
| 02/13/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/08/2023 |
3
| Velan Capital Investment Management LP (See Footnote 2) has filed a Form 3 on HERON THERAPEUTICS, INC. /DE/ |
| 02/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/27/2023 |
SC 13G/A
| Velan Capital Investment Management LP reports a 10.2% stake in Jasper Therapeutics, Inc. |
| 01/06/2023 |
SC 13G
| Velan Capital Investment Management LP reports a 8.8% stake in Edesa Biotech, Inc. |
| 08/26/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/12/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/11/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/24/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/21/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/17/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/13/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/07/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 06/06/2022 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 05/25/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/24/2022 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/18/2022 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 04/18/2022 |
SC 13D/A
| Velan Capital Investment Management LP reports a 3.3% stake in Radius Health, Inc. |
| 03/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/07/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
|
|